ERBB2 and breast carcinoma: Although saturation was determined to have been achieved for symptoms/side effects, suggesting that these concepts are the key features of the HR+/HER2- advanced breast cancer experience, there is a possibility that because of the specific breast cancer subtype and treatments received, these results may not be generalizable to the wider advanced breast cancer population.